The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Dedicated clinical trial tissue tracking database to improve turn-around time at high-volume center.
 
Peter Blankenship
Employment - HCA/Sarah Cannon
 
David DeLaRosa
Employment - Sarah Cannon Research Institute
 
Marc Burris
Employment - HCA Healthcare
Stock and Other Ownership Interests - HCA Healthcare; HCA Healthcare (I)
Travel, Accommodations, Expenses - HCA Healthcare (I)
 
Steven Cusson
Employment - Sarah Cannon Research Institute
 
Kayla Hendricks
Employment - HCA/Sarah Cannon
 
Christopher Earwood
No Relationships to Disclose
 
Suzanne Fields Jones
Employment - HCA/Sarah Cannon
Stock and Other Ownership Interests - HCA Healthcare
Consulting or Advisory Role - Amgen (Inst)
 
Erika P. Hamilton
Consulting or Advisory Role - Arvinas (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dantari (Inst); Deciphera (Inst); Eisai (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Lilly (Inst); Merck (Inst); Mersana (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Seagen (Inst); Silverback Therapeutics (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Akeso Biopharma (Inst); Amgen (Inst); ArQule (Inst); Arvinas (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Compugen (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dana Farber Cancer Hospital (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Fochon Pharmaceuticals (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Harpoon (Inst); Hutchison MediPharma (Inst); Immunogen (Inst); Immunomedics (Inst); Infinity Pharmaceuticals (Inst); InventisBio (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Lilly (Inst); Lycera (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Molecular Templates (Inst); Novartis (Inst); Nucana (Inst); Olema Pharmaceuticals (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); Orinove (Inst); Pfizer (Inst); PharmaMar (Inst); Plexxikon (Inst); Polyphor (Inst); Puma Biotechnology (Inst); Radius Health (Inst); Regeneron (Inst); Rgenix (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Shattuck Labs (Inst); Silverback Therapeutics (Inst); Stem CentRx (Inst); Sutro Biopharma (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Torque (Inst); Torque (Inst); Verastem (Inst); Zenith Epigenetics (Inst); Zymeworks (Inst)
 
Melissa Lynne Johnson
Consulting or Advisory Role - Abbvie (Inst); Achilles Therapeutics (Inst); Amgen (Inst); Association of Community Cancer Centers (ACCC) (Inst); Astellas Pharma (I); AstraZeneca (Inst); Atreca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Checkpoint Therapeutics (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Guardant Health (Inst); Incyte (Inst); Janssen Oncology (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Otsuka (I); Pfizer (Inst); Ribon Therapeutics (Inst); Sanofi (Inst); WindMIL (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Adaptimmune (Inst); Amgen (Inst); Apexigen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Artios (Inst); AstraZeneca (Inst); Atreca (Inst); BeiGene (Inst); BerGenBio (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Checkpoint Therapeutics (Inst); Corvus Pharmaceuticals (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dracen (Inst); Dynavax Technologies (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Guardant Health (Inst); Hengrui Pharmaceutical (Inst); Immunocore (Inst); Incyte (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Kadmon (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); Merck (Inst); Mirati Therapeutics (Inst); Neovia Oncology (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst); PMV Pharma (Inst); Regeneron (Inst); Ribon Therapeutics (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Seven and Eight Biopharmaceuticals (Inst); Shattuck Labs (Inst); Silicon Therapeutics (Inst); Stem CentRx (Inst); Syndax (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TCR2 Therapeutics (Inst); Tmunity Therapeutics, Inc. (Inst); University of Michigan (Inst); WindMIL (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech; Incyte; Merck; Pfizer; Sanofi
 
Howard A. Burris III
Employment - HCA Healthcare
Leadership - HCA Healthcare
Stock and Other Ownership Interests - HCA Healthcare
Consulting or Advisory Role - AstraZeneca (Inst); Celgene (Inst); FORMA Therapeutics (Inst); Incyte (Inst); Novartis (Inst)
Research Funding - Agios (Inst); Archer (Inst); Array BioPharma (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); BIND Therapeutics (Inst); BioAtla (Inst); BioMed Valley Discoveries (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CicloMed (Inst); CytomX Therapeutics (Inst); eFFECTOR Therapeutics (Inst); Foundation Medicine (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Harpoon therapeutics (Inst); Incyte (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Kymab (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); miRNA Therapeutics (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Revolution Medicines (Inst); Roche/Genentech (Inst); Seagen (Inst); Takeda/Millennium (Inst); Tesaro (Inst); TG Therapeutics (Inst); Verastem (Inst); Vertex (Inst)
Expert Testimony - Novartis (Inst)
(OPTIONAL) Uncompensated Relationships - Bayer (Inst); Daiichi Sankyo (Inst); GRAIL (Inst); Novartis (Inst); Pfizer (Inst); Vincerx Pharma (Inst)
 
Johanna C. Bendell
Consulting or Advisory Role - Amgen (Inst); Apexigen (Inst); Arch Oncology (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Bicycle Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Cerulean Pharma (Inst); Continuum Clinical (Inst); Cyteir (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); Five Prime Therapeutics (Inst); FORMA Therapeutics (Inst); Fusion Pharmaceuticals (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Innate Pharma (Inst); Ipsen (Inst); Janssen (Inst); Kyn therapeutics (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Merrimack (Inst); Moderna Therapeutics (Inst); Molecular Partners (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Phoenix Biotech (Inst); Prelude Therapeutics (Inst); Relay Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Tanabe Research (Inst); TD2 (Inst); TG Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Tolero Pharmaceuticals (Inst); Torque (Inst)
Research Funding - Abbott/AbbVie (Inst); Acerta Pharma (Inst); ADC Therapeutics (Inst); Agios (Inst); Amgen (Inst); Apexigen (Inst); Arch Oncology (Inst); Arcus Biosciences (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); Arrys Therapeutics (Inst); AstraZeneca/MedImmune (Inst); AtlasMedx (Inst); Bayer (Inst); BeiGene (Inst); Bellicum Pharmaceuticals (Inst); Bicycle Therapeutics (Inst); BioNTech (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); cyteir (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); Elicio Therapeutics (Inst); EMD Serono (Inst); EMD Serono (Inst); Erasca, Inc (Inst); Evelo Therapeutics (Inst); Evelo Therapeutics (Inst); Five Prime Therapeutics (Inst); FORMA Therapeutics (Inst); Forty Seven (Inst); Forty Seven (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gossamer Bio (Inst); Gritstone Bio (Inst); Harpoon therapeutics (Inst); Harpoon therapeutics (Inst); Hutchison MediPharma (Inst); IGM (Inst); ImClone Systems (Inst); Incyte (Inst); Innate Pharma (Inst); Innate Pharma (Inst); Ipsen (Inst); Jacobio (Inst); Janssen (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Loxo/Lilly (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); Marshall Edwards (Inst); Merck (Inst); Merrimack (Inst); Mersana (Inst); Merus (Inst); Millenium Pharamceuticals (Inst); Molecular Partners (Inst); Nektar (Inst); NeoImmuneTech (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Novocure (Inst); Numab (Inst); Oncogenex (Inst); OncoMed (Inst); Onyx (Inst); Pfizer (Inst); Phoenix Biotech (Inst); Pieris Pharmaceuticals (Inst); Pionyr (Inst); Prelude Therapeutics (Inst); PureTech (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Repare Therapeutics (Inst); Revolution Medicines (Inst); Rgenix (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Scholar Rock (Inst); Seagen (Inst); Shattuck Labs (Inst); Sierra Oncology (Inst); Sorrento Therapeutics (Inst); Stem CentRx (Inst); SynDevRx (Inst); Synthorx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tempest Therapeutics (Inst); TG Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Torque (Inst); TRACON Pharma (Inst); Treadwell Therapeutics (Inst); Tyrogenex (Inst); Unum Therapeutics (Inst); Vyriad (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - ARMO BioSciences; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; FORMA Therapeutics; Gilead Sciences; Ipsen; Lilly; MedImmune; Merck; Novartis; OncoMed; Roche/Genentech; Taiho Pharmaceutical
 
Meredith McKean
Consulting or Advisory Role - Array BioPharma (Inst); AstraZeneca (Inst); Pfizer (Inst); Regeneron (Inst)
Research Funding - Ascentage Pharma Group (Inst); Bicycle Therapeutics (Inst); Dragonfly Therapeutics (Inst); Epizyme (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); IDEAYA Biosciences (Inst); Ikena Oncology (Inst); Infinity Pharmaceuticals (Inst); Jacobio (Inst); Moderna Therapeutics (Inst); NBE Therapeutics (Inst); Novartis (Inst); Oncorus (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Tizona Therapeutics, Inc. (Inst); Tmunity Therapeutics, Inc. (Inst); Top Alliance BioScience (Inst)